1. Lilly says its monoclonal antibody prevented COVID-19 infections in trial — Roche gets priority review on blockbuster IPF drug — California says batch of Moderna vaccine is safe, despite reports of illnesses — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Latest News - ADU won't be approved

Discussion in 'BiogenIdec' started by anonymous, Oct 19, 2020 at 9:26 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    And Reimbursement Manager Director level job just posted in CA. Does corporate not have an ounce of sense our conscience?
     

  2. anonymous

    anonymous Guest

    so true!
     
  3. anonymous

    anonymous Guest

    15k applicants my ass!
     
  4. anonymous

    anonymous Guest

    Well I guess there are 15K desperate unemployed reps out there.

    To be honest I would guess half were running from something, another quarter were unemployed, and the other quarter never look before jumping into a burning dumpster so long as the short term money looks right.
     
  5. anonymous

    anonymous Guest

    You can post anonymous comments and thoughts regarding Aducanumab on the FDA's website whether good or bad at -

    regulations.gov/comment?D=FDA-2018-N-0410-0024

    Most consider there is an obvious lack of sufficient data to be approved.
     
  6. anonymous

    anonymous Guest


    I heard the majority of the panel would recommend. I heard 9 of them are solid. Isn't that the case?
     
  7. anonymous

    anonymous Guest

    I heard no way, more studies needed
     
  8. anonymous

    anonymous Guest

    There is a very long list of concerns. This fact alone speaks to the need for more data. It just isn't clear cut and concerns about safety and cost are a big deal. The FDA will see that this is very complex and it will require more time.
     
  9. anonymous

    anonymous Guest

    Adcomm meeting will tell our fate. No one on here knows a damn thing. All speculation at this point. Funny how so many people think they’re smarter than multi billion dollar company. If this doesn’t work out so be it. Life is full of risk. A bunch of anonymous genius Pharma heads claiming it won’t get approved. Hilarious lololol.
     
  10. anonymous

    anonymous Guest

    Oh yeah? Well you are the douche bag who spends their time reading all the posts. Who is an idiot now? YOU ARE.
     
  11. anonymous

    anonymous Guest


    The panel from America’s Got Talent doesn’t get a vote. You heard? From your cousins former roommate who knows a guy...that knows another guy who sits on the Advisory committee. You’re the sperm your mother should of swallowed.
     
  12. anonymous

    anonymous Guest

    They have reached out to all the members of the advisory committee and have collected each and every stance, you idiot. You are such a complete moron.
     
  13. anonymous

    anonymous Guest

    What the f are you babbling about?
     
  14. anonymous

    anonymous Guest

    My ADU Manager today told me she is looking for a new job, and recommended I do the same. Internally, they are bailing on the thought this will get approved any time in the next 2 years.
     
  15. anonymous

    anonymous Guest


    Sometimes the best jobs you get are the ones you are not hired for. Arrogant DM turned me down, so who is laughing now?? I will throw a dollar in your bowel when a pass you by, sucker
     
  16. anonymous

    anonymous Guest

    Throw a dollar in your bowel? That's some Voodoo, Kung Fu type shit. Show us this magic, Chuck Norris.
     
  17. anonymous

    anonymous Guest


    We should be hearing approval any
    day now, should be soon the stock
    experts predicting.
     
  18. anonymous

    anonymous Guest

     
  19. anonymous

    anonymous Guest

    Should be approved now any day ,hopefully by Christmas at latest.
     
  20. anonymous

    anonymous Guest

    The advisory board will certainly bring up issues with safety and certainly the absolute requirement for a REMS program, lack of efficacy and the necessary development of a third phase three trial. Medical agencies across the United States have expressed a multitude of concerns that will take months, perhaps years, to weed through and satisfy. The FDA has the responsibility for public safety and ample efficacy and this hasn't been demonstrated yet. This is a test run to see how FDA deals with all these issues and all the other Alzheimer's invested pharmaceutical companies will use this as a gauge.